首页> 外文OA文献 >Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors

【2h】

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors

机译：达可替尼（PF-00299804）的I期和药代动力学研究，它是一种口服不可逆的人类表皮生长因子受体-1，-2和-4酪氨酸激酶的小分子抑制剂，用于患有晚期实体瘤的日本患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. [J] . Toshiaki Takahashi, Narikazu Boku, Haruyasu Murakami, Investigational new drugs. . 2012,第6期

机译：达可替尼（PF-00299804）的I期和药代动力学研究，它是一种在日本患有晚期实体瘤的人类表皮生长因子受体-1，-2和-4酪氨酸激酶的不可逆口服小分子抑制剂。
2. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. [J] . Karen L Reckamp, Giuseppe Giaccone, D Ross Camidge, Cancer: A Journal of the American Cancer Society . 2014,第8期

机译：达莫替尼（PF-00299804）（一种口服，不可逆的pan-HER（人类表皮生长因子受体）抑制剂）在先前化疗和厄洛替尼治疗失败后的晚期非小细胞肺癌患者中进行的2期试验。
3. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. [J] . Karen L Reckamp, Giuseppe Giaccone, D Ross Camidge, Cancer: A Journal of the American Cancer Society . 2014,第8期

机译：在前化学疗法失败后，Dacomitinib（PF-00299804），口腔不可逆的PAN-SEN（人表皮生长因子受体）抑制剂，患有先进的非小细胞肺癌患者的阶段试验。
4. The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 (Iressa) Suppresses Proliferation and Invasion of Human Oral Squamous Carcinoma Cells via p53 Independent and MMP, uPAR Dependent Mechanism [C] . EUN JU LEE, JIN HA WHANG, NAM KYEONG JEON, Meeting on Cell Signaling World: Signal Transduction Pathways as Therapeutic Targets . 2007

机译：表皮生长因子受体酪氨酸激酶抑制剂ZD1839（Iressa）通过独立于p53和MMP，uPAR依赖性机制抑制人口腔鳞状细胞癌细胞的增殖和侵袭
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Phase I and pharmacokinetic study of dacomitinib (PF-00299804) an oral irreversible small molecule inhibitor of human epidermal growth factor receptor-1 -2 and -4 tyrosine kinases in Japanese patients with advanced solid tumors [O] . Toshiaki Takahashi, Narikazu Boku, Haruyasu Murakami, -1

机译：达可替尼（PF-00299804）的I期和药代动力学研究它是一种口服不可逆的人类表皮生长因子受体-1-2和-4酪氨酸激酶的小分子抑制剂用于患有晚期实体瘤的日本患者
7. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. [O] . Ramalingam, SS, Blackhall, F, Krzakowski, M, 2012

机译：晚期非小细胞肺癌患者中不可逆转的泛人类表皮生长因子受体抑制剂达可替尼（PF-00299804）的II期随机研究与厄洛替尼的比较。

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors

著录项

引文网络

相似文献

相关主题

期刊订阅